[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Shehab N, Sweet BV, Hogikyan ND: Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy; 2005 Jul;25(7):977-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature.
  • Recurrent respiratory papillomatosis (RRP) is a rare but potentially severe disease caused by papillomavirus, most often types 6 and 11.
  • The disease, which occurs in both juvenile and adult forms, is characterized by benign epithelial tumors of the airway that most frequently affect the larynx but can also spread along the entire aerodigestive tract.
  • Recurrent respiratory papillomatosis is the most common benign neoplasm of the larynx in children and the second most frequent cause of childhood hoarseness.
  • Standard treatment, which is palliative only, consists of surgical excision of papillomata to maintain airway patency and improve voice quality.
  • To date, incorporation of adjuvant treatments has not been reliably beneficial in altering the disease course.
  • To evaluate the data available on the safety and efficacy of cidofovir for the treatment of RRP, we conducted a MEDLINE search for all case reports or series from January 1966-August 2004 describing cidofovir therapy in either adults or children with RRP.
  • Further studies are necessary to determine the most appropriate dose, frequency, and duration of therapy, and to fully characterize the safety profile profile of cidofovir when given intralesionally.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Male


2. Elackattu AP, Feng L, Wang Z: A controlled safety study of diindolylmethane in the immature rat model. Laryngoscope; 2009 Sep;119(9):1803-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Diindolylmethane (DIM), a natural product from cruciferous vegetables, has been shown to be a dietary component that has inhibitory effects on some tumors (e.g., laryngeal papilloma).
  • METHODS: Forty rats were separated into four treatment groups of 10 rats each, based on the amount of study drug they received in their daily food:.
  • CONCLUSIONS: Diindolylmethane seems to have no adverse affects on the rat even when given in doses 3x what we propose to be therapeutic.
  • This adds evidence to the safety of this drug in the pediatric population as a treatment option for recurrent respiratory papilloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1161-72 [12479697.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 May;73(5):681-4 [19193450.001]
  • [Cites] J Voice. 2004 Jun;18(2):248-53 [15193659.001]
  • [Cites] J Toxicol Environ Health. 1987;21(3):311-23 [3495667.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):337-41 [8390800.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4569-73 [9891520.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):332-5 [15602729.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1320-7 [16385077.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4880-7 [16651444.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Sep;115(9):679-85 [17044539.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Sep;137(3):477-81 [17765779.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):661-4 [18642764.001]
  • [Cites] In Vivo. 2008 Jul-Aug;22(4):441-5 [18712169.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2619-24 [18843002.001]
  • [Cites] J Nutr. 2009 Jan;139(1):26-32 [19056653.001]
  • [Cites] J Cell Physiol. 2009 Apr;219(1):94-9 [19062173.001]
  • [Cites] Toxicol Sci. 2003 Jul;74(1):10-21 [12730619.001]
  • (PMID = 19544380.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287; United States / NIDCD NIH HHS / DC / 5R01DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / diindolylmethane; 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS115765; NLM/ PMC3015182
  •  go-up   go-down


3. Ruparelia S, Unger ER, Nisenbaum R, Derkay CS, Reeves WC: Predictors of remission in juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1275-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of remission in juvenile-onset recurrent respiratory papillomatosis.
  • OBJECTIVE: To determine factors associated with remission of juvenile-onset recurrent respiratory papillomatosis (JORRP).
  • INTERVENTIONS: Surgical excision and drug therapy.
  • MAIN OUTCOME MEASURES: Remission of JORRP, defined as no surgical procedures for at least 1 year, as associated with age at diagnosis, drug therapy in the first year after diagnosis, number of surgical procedures in the first year after diagnosis, and number of anatomical sites of disease at diagnosis.
  • [MeSH-major] Papilloma / therapy. Remission Induction. Respiratory Tract Neoplasms / therapy
  • [MeSH-minor] Age Distribution. Age Factors. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Medicaid. Multivariate Analysis. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Recurrence. Registries. Reoperation / statistics & numerical data. Survival Analysis. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676151.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Gerein V, Rastorguev E, Gerein J, Lodemann E, Pfister H, Draf W, Desloovere C: 2',5'-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papillomatosis. J Laryngol Otol; 2004 Oct;118(10):750-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2',5'-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papillomatosis.
  • OBJECTIVE: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course, as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis.
  • METHODS: Forty-two patients with recurrent respiratory papillomatosis were treated with interferon-alpha (3 MU/m(2) three times per week; mean therapy duration was 2.7 +/- 1.8 years) in 1983-1994 and followed-up until 2003.
  • Human papilloma virus (HPV) type, recurrent respiratory papillomatosis severity and 2',5'-oligoadenylate synthetase activity were determined by standard methods and analysed for correlation with the results of long-term clinical outcome.
  • RESULTS AND CONCLUSION: Patients with HPV type 11, a severity score >4, a high number of surgical procedures prior to interferon-alpha therapy and a high basal 2',5'-oligoadenylate synthetase activity should be considered at high risk of an aggressive clinical course, often with spread to lower airway passages, malignant transformation and death.
  • Human papilloma virus type, score for recurrent respiratory papillomatosis severity, number of surgical procedures and 2',5'-oligoadenylate synthetase activity showed significant association with response to interferon-alpha therapy and the long-term clinical course, so these factors have value in predicting prognosis in recurrent respiratory papillomatosis.
  • [MeSH-major] 2',5'-Oligoadenylate Synthetase / analysis. Papilloma / enzymology. Papillomaviridae / enzymology. Respiratory Tract Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. DNA, Viral / analysis. Female. Humans. Interferon-alpha / therapeutic use. Leukocytes, Mononuclear / enzymology. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / enzymology. Prognosis. Prospective Studies. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15550179.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / Interferon-alpha; EC 2.7.7.- / 2',5'-Oligoadenylate Synthetase
  •  go-up   go-down


5. Nagel S, Busch C, Blankenburg T, Schütte W: [Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab]. Pneumologie; 2009 Jul;63(7):387-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab].
  • [Transliterated title] Behandlung der respiratorischen Papillomatose--Kasuistik zur systemischen Therapie mit Bevacizumab.
  • BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a known but rare disease, caused by human papilloma virus and characterised by multiple exophytic lesions and uncontrolled growth of papilloma in the respiratory tract.
  • Medical therapeutic options have so far been less effective.
  • However, inhibition of vascular endothelial growth factor (VEGF) by bevacizumab does appear to be an effective treatment option for RRP.
  • CASE REPORT: The case of a 32-year-old male patient with RRP who has been treated for his symptomatic tracheal stenosis four times a year since 1996 is described.
  • Only treatment by laser ablation showed any efficacy.
  • Alternative treatment options did not show any effect.
  • During this treatment no further laser ablation was necessary.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19591084.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


6. Schraff S, Derkay CS, Burke B, Lawson L: American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg; 2004 Sep;130(9):1039-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.
  • OBJECTIVE: To evaluate how evolving treatment technologies have affected our management of recurrent respiratory papilloma (RRP) since the last comprehensive survey of pediatric otolaryngologists in 1998.
  • A total of 150 (21%) of these patients presently receive adjuvant medical therapies with cidofovir and interferon, accounting for more than two thirds of the total.
  • Distal spread of RRP has occurred in 94 (13%) of the 700 patients.
  • The laryngeal microdebrider (53%) has supplanted the carbon dioxide laser (42%) as the preferred means of surgically removing papilloma from the larynx in children.
  • Routine human papillomavirus subtyping is practiced by 45% of respondents while 15% treat all their patients with antireflux medications.
  • CONCLUSIONS: Recurrent respiratory papilloma continues to be a frustrating disease to treat and is associated with significant morbidity and mortality.
  • There has been an evolution in the past decade toward the increased use of antiviral adjuvant therapy and the use of microdebrider techniques for surgical management.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Australia. Chemotherapy, Adjuvant. Child. Child, Preschool. Debridement / methods. Europe. Health Care Surveys. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Microsurgery. North America. Organophosphorus Compounds / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15381589.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


7. Hamza AH, Nasr MM, Deghady AA: The use of mitomycin-C for respiratory papillomas: clinical, histologic and biochemical correlation. Saudi Med J; 2005 Nov;26(11):1737-45
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of mitomycin-C for respiratory papillomas: clinical, histologic and biochemical correlation.
  • OBJECTIVE: To assess the clinical effects of mitomycin-C (MMC) on human papilloma virus (HPV)-infected tissues of the airway.
  • METHODS: We included 10 patients with previous histologic diagnosis of recurrent respiratory papillomas (RRP) in this prospective study, conducted at the Department of Otolaryngology-Head and Neck Surgery, University of Alexandria, Egypt, between January 2000 and December 2002.
  • Under general anesthesia, each patient underwent laser excision of all visible papillomas, followed by topical application of 1 cc of 0.5 mg/ml MMC.
  • The procedure was repeated weekly until no visible papillomas could be microscopically detected.
  • The mean serum IL-2 levels+/- SD was significantly lower in papilloma patients (83.6+/- 28.83 pg/ml) than in control subjects (196.3+/- 42.46 pg/ml) (p<0.01).
  • [MeSH-major] Mitomycin / therapeutic use. Papilloma / drug therapy. Papilloma / virology. Papillomavirus Infections / drug therapy. Respiratory Tract Neoplasms / drug therapy. Respiratory Tract Neoplasms / virology
  • [MeSH-minor] Adolescent. Base Sequence. Biopsy, Needle. Child. Child, Preschool. DNA, Viral / analysis. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laryngoscopy. Male. Molecular Sequence Data. Neoplasm Staging. Papillomaviridae / drug effects. Papillomaviridae / isolation & purification. Polymerase Chain Reaction / methods. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Saudi Med J. 2006 Apr;27(4):572
  • (PMID = 16311658.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Duplicate Publication; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / DNA, Viral; 50SG953SK6 / Mitomycin
  •  go-up   go-down


8. Armbruster C: Novel treatments for recurrent respiratory papillomatosis. Expert Opin Investig Drugs; 2002 Aug;11(8):1139-48
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatments for recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis is a rare but often severe disease.
  • Although benign in histology, epithelial proliferations may result in progressive hoarseness, stridor, obstruction of the airway and respiratory distress.
  • The current standard of care is surgical therapy with a goal of complete removal or debulking of papillomas and preservation of normal structures.
  • Frequent recurrences and the need for repeated surgical interventions make this treatment a frustrating experience for both the patient and the physician.
  • Many adjuvant therapies have been investigated but no single treatment modality proved to be effective in eradicating recurrent respiratory papillomatosis.
  • In contrast to HIV, cytomegalovirus and hepatitis B pharmaceutical research has been less successful with human papilloma virus vaccines for a variety of reasons.
  • This review focuses on the current status of recurrent respiratory papillomatosis and on future directions of prevention and therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Papilloma / drug therapy. Papillomaviridae / drug effects. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Humans. Laser Therapy. Papillomavirus Infections / drug therapy. Papillomavirus Infections / surgery. Papillomavirus Infections / virology. Tumor Virus Infections / drug therapy. Tumor Virus Infections / surgery. Tumor Virus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150707.001).
  • [ISSN] 1354-3784
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 85
  •  go-up   go-down


9. Gupta HT, Robinson RA, Murray RC, Karnell LH, Smith RJ, Hoffman HT: Degrees of dysplasia and the use of cidofovir in patients with recurrent respiratory papillomatosis. Laryngoscope; 2010 Apr;120(4):698-702
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Degrees of dysplasia and the use of cidofovir in patients with recurrent respiratory papillomatosis.
  • OBJECTIVES/HYPOTHESIS: Recurrent respiratory papillomatosis (RRP) is a benign disease characterized by recurrent lesions in the airway.
  • Adjuvant therapies, such as cidofovir, have been tried with the goal of decreasing the interval between repeat surgical treatments, the mainstay of therapy.
  • This study aims to explore the association between increasing degree of papilloma dysplasia and the use of cidofovir in the context of the natural progression of dysplasia in RRP.
  • Pathologic data collected over 10 years from serial excisions at the University of Iowa Hospitals were reviewed by a single pathologist, and the highest degree of dysplasia was noted per excision time.
  • RESULTS: Of the 176 specimens collected in these 13 patients with serial papilloma biopsies, 5.7% had no dysplasia, 57.4% had mild dysplasia (grade 1), 28.4% had moderate dysplasia (grade 2), and 8.5% had severe dysplasia (grade 3).
  • A comparison of each patient's multiple biopsies across time suggested that the dysplastic grade was worse in two patients, better in four patients, and virtually unchanged in seven patients.
  • There was no clear-cut pattern between the use of cidofovir and the degree of dysplasia over time.
  • CONCLUSIONS: These results strongly suggest that intralesional cidofovir therapy does not correlate with worsening dysplastic progression.
  • [MeSH-major] Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Respiratory Mucosa / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Papilloma. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205173.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


10. Donne AJ, Rothera MP, Homer JJ: Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol; 2008 Jul;72(7):939-44
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.
  • OBJECTIVE: Cidofovir is the most contemporary adjuvant treatment for recurrent respiratory papillomatosis (RRP) and its use is increasing.
  • Otolaryngologists should understand the science of cidofovir and review the current published data on the effects of this therapy.
  • RESULTS: Thirteen articles were identified between 1998 and 2006, representing the treatment of 142 patients.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Organophosphonates / therapeutic use. Papilloma / drug therapy. Papillomavirus Infections / drug therapy. Respiratory Tract Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502519.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 40
  •  go-up   go-down


11. Rosen CA, Bryson PC: Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice; 2004 Jun;18(2):248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results.
  • We report the results of a clinical study using Indole-3-Carbinol (I3C) for the treatment of recurrent respiratory papillomatosis (RRP).
  • I3C has been found to be a successful treatment option for RRP.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Indoles / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15193659.001).
  • [ISSN] 0892-1997
  • [Journal-full-title] Journal of voice : official journal of the Voice Foundation
  • [ISO-abbreviation] J Voice
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Indoles; C11E72455F / indole-3-carbinol
  •  go-up   go-down


12. Chadha NK, James AL: Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev; 2005;(4):CD005053
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant antiviral therapy for recurrent respiratory papillomatosis.
  • BACKGROUND: Recurrent respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the upper airway.
  • Treatment usually involves repeated surgical debulking of the papillomata, and several agents have been proposed as adjuvants to surgical debulking.
  • OBJECTIVES: To assess the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children and adults.
  • AUTHORS' CONCLUSIONS: There was insufficient evidence from controlled trials on which to base reliable conclusions about the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis.
  • Further research is required before any specific antiviral adjuvant therapy can be recommended.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Airway Obstruction / drug therapy. Airway Obstruction / virology. Chemotherapy, Adjuvant. Child. Humans. Recurrence

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2010;(1):CD005053 [20091568.001]
  • (PMID = 16235390.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 19
  •  go-up   go-down


13. Limsukon A, Susanto I, Soo Hoo GW, Dubinett SM, Batra RK: Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest; 2009 Sep;136(3):924-926
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
  • Recurrent respiratory papillomatosis (RRP) can be difficult to manage.
  • Symptoms are related to recurrent tracheobronchial papillomas and are usually treated with bronchoscopic removal.
  • Other modalities are added when the papilloma burden becomes too great or recurrence is too frequent, but with limited efficacy.
  • We report a patient with progressive RRP that had become refractory to available therapy.
  • Because papillomas overexpress epidermal growth factor receptor, along with increased expression of cyclooxygenase-2 and prostaglandin E2, it was reasoned that a combination therapy of erlotinib and celecoxib would be effective in controlling papilloma growth.
  • There was a striking improvement in the number and appearance of respiratory tract papillomas, with elimination of the need for repeated papilloma removal.
  • Pretreatment and posttreatment images document this response, and the improvement has now been maintained for nearly 2 years with effective therapy.
  • [MeSH-major] Cyclooxygenase Inhibitors / therapeutic use. Laryngeal Neoplasms / drug therapy. Papilloma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Biopsy. Bronchoscopy. Celecoxib. Drug Therapy, Combination. Erlotinib Hydrochloride. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736197.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Protein Kinase Inhibitors; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; DA87705X9K / Erlotinib Hydrochloride; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


14. Chadha NK, James A: Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev; 2010;(1):CD005053
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant antiviral therapy for recurrent respiratory papillomatosis.
  • BACKGROUND: This is an update of a Cochrane Review originally published in Issue 4, 2005 of The Cochrane Library.Recurrent respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the upper airway.
  • Treatment usually involves repeated surgical debulking of the papillomata.
  • OBJECTIVES: To assess the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children and adults.
  • MAIN RESULTS: The included study was a single-institution, randomised, double-blind, placebo-controlled trial of intralesional cidofovir administered at the time of surgical debulking.
  • Both groups showed a significant reduction in disease extent (as assessed at the time of surgery using the Derkay Scoring System), but no significant change in health-related quality of life.
  • AUTHORS' CONCLUSIONS: There is insufficient evidence to support the efficacy of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children or adults.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Airway Obstruction / drug therapy. Airway Obstruction / virology. Chemotherapy, Adjuvant. Child. Humans. Recurrence

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;12:CD005053 [23235619.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(4):CD005053 [16235390.001]
  • (PMID = 20091568.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 27
  •  go-up   go-down


15. Akst LM, Lee W, Discolo C, Knott D, Younes A, Koltai PJ: Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg; 2003 Aug;129(8):841-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children.
  • OBJECTIVE: To evaluate a stepped-dose protocol for intralesional injection of cidofovir in children with recurrent respiratory papillomatosis (RRP).
  • INTERVENTION: Intralesional injection of cidofovir was performed after microlaryngoscopy and carbon dioxide laser treatment.
  • OUTCOME MEASURE: Papilloma stage (0-3) documented at multiple subsites by means of serial microlaryngoscopy.
  • RESULTS: The severity score decreased in each of the 11 patients during the course of therapy, from a mean +/- SD of 13.7 +/- 6.0 at enrollment to 2.1 +/- 3.4 at 1-month follow-up.
  • Six patients experienced complete resolution (stage 0) and 4 others had mild disease (stage, </=5) after 4 treatments at the 5-mg/mL concentration.
  • Five patients with residual or recurrent RRP subsequently started a series of 4 cidofovir treatments at a concentration of 10 mg/mL, with a mixed response.
  • Patients with persistent or recurrent disease may benefit from an increased cidofovir concentration of 10 mg/mL, although some aggressive papillomatous disease remains refractory to cidofovir treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Injections, Intralesional. Laryngoscopy. Laser Therapy. Male. Prospective Studies. Severity of Illness Index. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12925342.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


16. Silverman DA, Pitman MJ: Current diagnostic and management trends for recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg; 2004 Dec;12(6):532-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnostic and management trends for recurrent respiratory papillomatosis.
  • PURPOSE OF REVIEW: The purpose of this review is to discuss recent literature regarding diagnostic and management trends for recurrent respiratory papillomatosis (RRP) published within the past year.
  • This includes a discussion of new information regarding the epidemiology and pathogenesis of RRP and an update on adjuvant therapy and new surgical techniques.
  • Distal tracheal or pulmonary RRP is rare, but carries a significant increase in morbidity and mortality.
  • At the present time, surgery remains the mainstay of treatment for RRP.
  • However, recurrence after surgery is common and the search for effective adjuvant therapies is ongoing.
  • The antiviral drug cidofovir has demonstrated efficacy against RRP and is considered a promising new adjuvant treatment of this disease.
  • In an attempt to minimize the untoward effects of surgery, the pulsed-dye laser (PDL) has emerged as a safe and efficacious treatment for select patients with RRP.
  • Significant advances in clinical and basic science research have dramatically improved our understanding of the epidemiology and pathogenesis of the disease and led to the development of promising new adjuvant therapies and surgical techniques.
  • [MeSH-major] Cytosine / analogs & derivatives. Papilloma / diagnosis. Papilloma / surgery. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Humans. Neoplasm Recurrence, Local. Organophosphonates / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15548913.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 30
  •  go-up   go-down


17. McMurray JS, Connor N, Ford CN: Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol; 2008 Jul;117(7):477-83
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study.
  • OBJECTIVES: We performed a prospective, double-blind, placebo-controlled, longitudinal adjuvant therapy trial to determine the efficacy of cidofovir in the treatment of severe recurrent respiratory papillomatosis (RRP).
  • Although results of case series suggest that cidofovir may decrease the frequency and rapidity of papilloma regrowth, no blinded placebo-controlled studies have demonstrated efficacy.
  • METHODS: Adults and children (n = 19) with aggressive RRP received either active drug (cidofovir) or placebo.
  • When surgical intervention was needed, drug or placebo was injected into affected areas after surgical removal of disease.
  • The following measures were made at baseline and at 2-month intervals for the course of 12 months: Derkay papilloma severity grading scale, Voice Handicap Index, Health-Related Quality of Life, and total number of procedures performed over 12 months.
  • Accordingly, we were unable to provide proof of efficacy of cidofovir in the treatment of RRP.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700421.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


18. Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, Berger B, Neefe JR: HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol; 2005 Sep;114(9):730-7
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial.
  • OBJECTIVES: We sought to evaluate the effectiveness of HspE7, a recombinant fusion protein of Hsp65 from Mycobacterium bovis BCG and E7 protein from human papillomavirus 16, to improve the clinical course of pediatric patients with recurrent respiratory papillomatosis.
  • Twenty-seven male and female patients with recurrent respiratory papillomatosis, ages 2 to 18 years, were enrolled and followed up to 60 weeks.
  • The primary end point was the length of the interval from the last surgery during the treatment period until the first debulking surgery in the posttreatment period, compared with the median intersurgical interval (ISI) of the 4 surgeries before the treatment.
  • The median ISI for all surgeries after treatment was similarly prolonged (mean, 107 days; p < .02), indicating a sustained treatment effect, and was associated with a significant decrease in the number of required surgeries (p < .003).
  • Unexpectedly, the treatment effect was most striking in the 13 female patients, who had statistically significant increases in both the first posttreatment ISI (142%; p < .03) and the median ISI (147%; p < .03).
  • CONCLUSIONS: Treatment with HspE7 appears to significantly improve the clinical course in pediatric patients with RRP insofar as it reduces the frequency of required surgeries.
  • [MeSH-major] Bacterial Proteins / therapeutic use. Chaperonins / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Oncogene Proteins, Viral / therapeutic use. Papilloma / drug therapy. Recombinant Fusion Proteins / therapeutic use. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chaperonin 60. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Papillomaviridae / drug effects. Papillomavirus E7 Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240938.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Chaperonin 60; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / heat-shock protein 65, Mycobacterium; 0 / oncogene protein E7, Human papillomavirus type 16; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


19. Nodarse-Cuní H, Iznaga-Marín N, Viera-Alvarez D, Rodríguez-Gómez H, Fernández-Fernández H, Blanco-López Y, Viada-González C, López-Saura P, Cuban Group for the Study of Interferon in Recurrent Respiratory Papillomatosis: Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report). J Laryngol Otol; 2004 Sep;118(9):681-7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report).
  • Respiratory papillomatosis is a life-spoiling disease due to its high recurrence rate.
  • Interferon (IFN)alpha-2b treatment, adjuvant to surgery, was assessed for its contribution to disease control and patient quality of life improvement.
  • One hundred and sixty-nine patients (85 children and 84 adults) were included after surgical removal of the lesions followed by intramuscular IFN alpha-2b (Heberon alfa R, Heber Biotec), starting with 10(5) IU/Kg weight in children or 6 x 10(6) IU in adults, three times per week.
  • Among patients included after their first papilloma, 67 per cent (44/66) had complete (no relapses) or partial (only one relapse) responses (children: 15/33, 45 per cent; adults 29/33, 88 per cent).
  • One hundred and eighteen patients (73 per cent) concluded the treatment without lesions (children: 58 per cent; adults 82 per cent), while the rest showed a significant reduction in the number and size of lesions.
  • One patient developed anti-IFN alpha neutralizing antibodies and became resistant to treatment with recombinant IFN alpha-2b; he responded to natural leucocyte IFN alpha.
  • Treatment with IFN alpha-2b, as an adjuvant to surgery represents a favourable and safe therapeutic alternative for patients with recurrent respiratory papillomatosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Interferon-alpha / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Male. Middle Aged. Recombinant Proteins / therapeutic use. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517700.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


20. Pransky SM, Brewster DF, Magit AE, Kearns DB: Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg; 2000 Oct;126(10):1239-43
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis.
  • OBJECTIVES: To continue assessment of the benefits and risks of intralesional administration of cidofovir, an acyclic nucleoside phosphonate, for treating severe recurrent respiratory papillomatosis (RRP) in pediatric patients, and to discuss guidelines for larger prospective multi-institutional studies of the use of cidofovir.
  • PATIENTS: A total of 10 patients with severe RRP (defined as requiring debulking procedures to maintain airway patency at least once a month) underwent intralesional cidofovir therapy.
  • INTERVENTION: Microsuspension laryngoscopy with intralesional injection of cidofovir after repetitive carbon dioxide laser treatments and mechanical debulking of papillomas.
  • MAIN OUTCOME MEASURES: Papilloma stage at the time of serial laryngoscopies.
  • Histologic examination of biopsy specimens of laryngeal tissue obtained 1 year or more after last cidofovir injection.
  • CONCLUSIONS: Intralesional cidofovir therapy continues to show benefit in the treatment of severe RRP in pediatric patients.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Injections, Intralesional. Male. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11031411.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


21. Peyton Shirley W, Wiatrak B: Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children? Int J Pediatr Otorhinolaryngol; 2004 Apr;68(4):413-8
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children?
  • OBJECTIVE: To assess the usefulness of cidofovir in treating recurrent respiratory papillomatosis in children.
  • Cidofovir is an acyclic nucleoside phosphonate that has been reported to be effective in the treatment of respiratory papillomatosis in several small series of patients.
  • METHODS: A prospective study was conducted in 11 children (mean, 2.1 years; range, 0.5-3 years at diagnosis) with recurrent respiratory papillomatosis who at the start of the study were requiring debridement of papillomas at least every 6 weeks.
  • After microlaryngoscopy with powered microdebridement of papillomas patients received intralesional injection of cidofovir (5mg/ml).
  • The severity of papillomatosis was rated at each visit using a standardized papilloma severity scoring system.
  • The success of therapy was measured by the trend in the patient's papilloma severity scores before and after cidofovir therapy and by whether the frequency of operative interventions decreased in the period after treatment began.
  • CONCLUSIONS: Intralesional cidofovir did not decrease the severity or frequency of operative intervention for recurrent respiratory papillomas in the majority of children in this study.
  • The drug did improve papillomatosis in the minority of patients without causing notable morbidity.
  • A large multi-institutional controlled study is needed to better assess the efficacy of this treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Child, Preschool. Debridement. Female. Humans. Infant. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15013606.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


22. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • Final pathologic analysis revealed an extensive infiltrative well-differentiated SCC arising from the papilloma.
  • A review of the literature on aggressive respiratory papillomatosis suggests that malignant transformation of juvenile-onset RRP occurs exclusively in cases positive for HPV-11.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chhetri DK, Shapiro NL: A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch Otolaryngol Head Neck Surg; 2003 Oct;129(10):1081-5
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir.
  • OBJECTIVE: To assess the efficacy of treating juvenile recurrent respiratory papillomas with intralesional cidofovir using a scheduled treatment protocol.
  • PATIENTS: Of 5 pediatric patients with recurrent respiratory papillomas, 2 had severe recurrent papillomatosis requiring long-term therapy of laser ablations every 2 weeks prior to cidofovir treatments.
  • The first 4 treatments were at 2-week intervals (week 0, 2, 4, and 6).
  • Subsequent treatment intervals were each increased by 1 week (treatments took place at week 9, 13, 18, 24, etc).
  • MAIN OUTCOME MEASURES: Papilloma stage and need for laser ablation at each scheduled visit.
  • RESULTS: The mean follow-up time was 66 weeks.
  • The mean (SD) papilloma stage decreased from 9.2 (5.5) at initial presentation to 3.4 (2.6) within 2 weeks of the first injection (P<.05), and continued to decrease for the remaining of the follow-up period.
  • Papilloma stage 0 was achieved in 4 of the 5 patients.
  • The need for laser ablation of papillomas also decreased within 4 weeks of treatment initiation (P<.05).
  • At 9 weeks, no patient required laser therapy.
  • CONCLUSION: An intralesional treatment protocol with cidofovir and increasing intervals between scheduled treatment was successful the long-term management of juvenile respiratory papillomatosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Protocols. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14568791.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


24. Szyfter W, Wierzbicka M, Jackowska J, Bartochowska A, Banaszewski J: [The schedule of intralesional papillomatosis treatment with cidofovir]. Otolaryngol Pol; 2010 Mar-Apr;64(2):98-102
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The schedule of intralesional papillomatosis treatment with cidofovir].
  • INTRODUCTION: Recurrent respiratory papillomatosis (RRP) is a rare disease in children and adults.
  • It is characterized by proliferation of benign squamous cell papillomas within the respiratory-digestive tract, predominantly the larynx.
  • Standard treatment consists of surgical excision of papillomata to maintain airway patency and voice quality.
  • For last several years cidofovir is the most contemporary adjuvant anti-viral treatment for recurrent respiratory papillomatosis and its topical use is widely described.
  • MATERIAL AND METHODS: Intralesional cidofovir therapy was given to 20 patients treated for laryngeal papillomas in the Department of Otolaryngology in Poznan between I-XII.2009.
  • The number of cidofovir injections per patient varied from one to six times and the volume of solution ranges from 1-12 ml.
  • CONCLUSIONS: Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Poland. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568538.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


25. Soma MA, Albert DM: Cidofovir: to use or not to use? Curr Opin Otolaryngol Head Neck Surg; 2008 Feb;16(1):86-90
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Cidofovir is an antiviral agent that has been used increasingly in the last decade as an adjuvant therapy for recurrent respiratory papillomatosis.
  • It has been used in patients with moderate to severe recurrent respiratory papillomatosis requiring frequent surgical intervention or if there is evidence of distal spread.
  • Intralesional administration after surgical debulking delivers the medication directly to the site of disease and is thought to have fewer systemic side effects than intravenous infusion.
  • RECENT FINDINGS: Despite its growing popularity, the potential risks related to cidofovir use in recurrent respiratory papillomatosis have not been well documented.
  • SUMMARY: Based on current opinion and research, it is likely that intralesional cidofovir will continue to have a role in the management of moderate to severe recurrent respiratory papillomatosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197029.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 30
  •  go-up   go-down


26. Van Valckenborgh I, Wellens W, De Boeck K, Snoeck R, De Clercq E, Feenstra L: Systemic cidofovir in papillomatosis. Clin Infect Dis; 2001 Feb 1;32(3):E62-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 8-year-old patient with severe recurrent respiratory papillomatosis and pulmonary spread was treated by systemic administration of cidofovir in association with laser treatment for tracheal lesions.
  • Complete disappearance of the lesions in the pharynx and larynx and a significant yet incomplete regression in the bronchi and lung parenchyma were observed without deleterious side effects.
  • This is the first case report of systemic use of cidofovir to treat recurrent respiratory papillomatosis.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Child. Female. Humans. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11170974.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


27. Seymour CW, Krimsky WS, Sager J, Kruklitis RJ, Lund ME, Musani AI, Sterman DH: Transbronchial needle injection: a systematic review of a new diagnostic and therapeutic paradigm. Respiration; 2006;73(1):78-89
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transbronchial needle injection: a systematic review of a new diagnostic and therapeutic paradigm.
  • METHODS AND RESULTS: By injecting lesions in the airways, peribronchial structures, mediastinum, or lung parenchyma, transbronchial needle injection has been applied to the treatment of lung cancer, inflammatory disorders of the airways, recurrent respiratory papillomatosis, as well as bronchopleural fistulas.
  • Diagnostic applications have included the localization of peripheral lung nodules as well as sentinel lymph nodes.
  • [MeSH-major] Bronchoscopy / methods. Catheterization. Cytosine / analogs & derivatives. Lung Diseases / diagnosis. Lung Diseases / therapy. Organophosphonates / administration & dosage
  • [MeSH-minor] Equipment Design. Humans. Injections. Lung Neoplasms / therapy. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy. Secondary Prevention. Solitary Pulmonary Nodule / diagnosis. Thoracic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • [CommentIn] Respiration. 2006;73(1):18-9 [16498270.001]
  • (PMID = 16498271.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 75
  •  go-up   go-down


28. Donne AJ, Hampson L, He XT, Day PJ, Salway F, Rothera MP, Homer JJ, Hampson IN: Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. Antivir Ther; 2009;14(7):939-52
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cidofovir is currently being used off-licence to treat different viral infections, such as benign low-risk human papillomavirus (HPV)-related recurrent respiratory papillomatosis (RRP).
  • Based on these results, gene expression microarray analysis was performed on cidofovir-treated low-risk E6 and vector cells before, during and after drug treatment, and the results verified by real-time PCR.
  • Microarray and real-time PCR analyses of low-dose cidofovir-treated low-risk E6-expressing cells revealed changes in gene expression that are known to be associated with malignant progression, which were not observed in drug-treated vector control cells.
  • It is our belief that these data provide cause for concern over the off-license use of this drug to treat RRP.
  • [MeSH-major] Antiviral Agents / adverse effects. Cytosine / analogs & derivatives. Organophosphonates / adverse effects. Papilloma / drug therapy. Papillomavirus Infections / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Cell Line. Cell Survival / drug effects. Gene Expression Profiling. Gene Expression Regulation / drug effects. Humans. Off-Label Use. Papillomaviridae / drug effects. RNA / biosynthesis. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19918098.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 63231-63-0 / RNA; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


29. Fletcher MA: Vaccine candidates in STD. Int J STD AIDS; 2002 Dec;13 Suppl 2:38-41
MedlinePlus Health Information. consumer health - Sexually Transmitted Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sexually transmitted diseases (STDs) are caused by organisms that infect the mucosal surfaces of the genitourinary tract.
  • In spite of its public health importance, current STD vaccine research lags behind work against pathogens that target another mucosal region, the respiratory tract.
  • Particular scientific problems have delayed STD vaccine development, like incomplete attenuation (human herpes simplex virus type 2), accentuated immunopathology (Chlamydia trachomatis), poor immunogenicity (Treponema pallidum), and broad antigenic heterogeneity (Neisseria gonorrhoeae).
  • Nevertheless, efforts continue with the use of protein antigens: for example, the haemolysin toxoid of Haemophilus ducreyi; the major outer membrane protein(s) of N. gonorrhoeae and C. trachomatis; the glycoprotein D of human herpes simplex virus type 2; and the proteins E6 and E7 of human papilloma virus.
  • It may be predicted that eventual STD vaccines (administered either for prophylaxis or for therapy) will use approaches that include (1) live-attenuated viruses, (2) subunit proteins or inactivated whole organisms given with mucosal adjuvants or with cellular immune response adjuvants, and (3) DNA plasmids expressing the vaccine antigen.
  • [MeSH-minor] Bacterial Vaccines / administration & dosage. Drug Design. Humans. Public Health. Vaccines, Attenuated / administration & dosage. Vaccines, Inactivated / administration & dosage

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12537725.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Vaccines; 0 / Vaccines; 0 / Vaccines, Attenuated; 0 / Vaccines, Inactivated
  •  go-up   go-down


30. Cullen RD, Zdanski C: Delivery of cidofovir to respiratory papillomas of the distal trachea. Laryngoscope; 2005 Mar;115(3):552-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delivery of cidofovir to respiratory papillomas of the distal trachea.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744176.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down






Advertisement